Name
BIRD
Alternate names
None
Primary Site
None
Histology
None
Radiation
None
Remarks
None
Drugs for BIRD
Name
Alternate Names
Aeroseb-Dex
AK-Dex
AK-Trol
Baldex
Component of Deronil
Component of Dexacidin
Component of Maxitrol
Dalalone
Decaderm
Decadrol
Decadron Tablets
Decajet
Decameth
Decasone
Decaspray
Deenar
Dex-4
Dexacen
Dexacidin
Dexacort Phosphate
Dexameth
Dexasone
Dexasporin
Dexone
Dexsone
Dezone
Gammacorten
Hexadrol
Hexadrol Elixir
Hexadrol Tablets
Infectrol Sterile
Maxidex
Maxitrol
Miral
Mymethasone
Neo-Dexameth
Neodecadron
Neodexair
Ocu-Trol
Oradexon
PMS-Dexamethasone Sodium Phosphate
SK-Dexamethasone
Sofracort
Sofradex
Solurex
Spersadex
Sterile Dexamethasone Acetate
Tobradex
Turbinare Decaron Phosphate
Abbreviations
DECA
DM
DSM
Category
Ancillary Agent
Hormones and hormonal mechanisms
Subcategory
Glucocorticoid. Probably not cancer directed--verify with attending MD.
NSC Number
345211
Primary Site
None
Histology
None
Remarks
NOTE* Dexamethasone may be coded as either an ancillary drug or hormone. Review chart to determine if given for supportive care or as hormonal therapy. IMPORTANT INFORMATION: dexamethasone is frequently included in treatment regimens, however, this does not indicate it should be coded as hormone therapy. Be sure to review the regimen tab in "Search Database" for additional coding information.
A long-acting corticosteroid (glucocorticoid). In general, this drug is used more commonly for supportive care, and as an antiemetic than it is as hormone therapy. 25 times as potent as cortisol; used topically as an anti-inflammatory and administered orally in replacement therapy for adrenal insufficiency, as an anti-inflammatory and immunosuppressant in a wide variety of disorders, and as an antiemetic in cancer chemotherapy. Dexamethasone and other corticosteroids may be used to control white cell proliferation in hematopoietic diseases and would be coded as hormone therapy for lymphoid leukemia, lymphoma and multiple myeloma.
A long-acting corticosteroid (glucocorticoid). In general, this drug is used more commonly for supportive care, and as an antiemetic than it is as hormone therapy. 25 times as potent as cortisol; used topically as an anti-inflammatory and administered orally in replacement therapy for adrenal insufficiency, as an anti-inflammatory and immunosuppressant in a wide variety of disorders, and as an antiemetic in cancer chemotherapy. Dexamethasone and other corticosteroids may be used to control white cell proliferation in hematopoietic diseases and would be coded as hormone therapy for lymphoid leukemia, lymphoma and multiple myeloma.
Coding
Please see remarks for additional information
Name
Alternate Names
Revlimid
lenalidomide
Abbreviations
None
Category
Biologic therapy (BRM, immunotherapy)
Subcategory
Cytostatic agent--antiangiogenesis agent
NSC Number
703813
Primary Site
5q- MDS
CLL
MDS
Multiple myeloma
melanoma
Lymphoma
Histology
None
Remarks
May 28, 2019: FDA approved lenalidomide (REVLIMID) in combination with a rituximab product for previously treated follicular lymphoma (FL) and previously treated marginal zone lymphoma (MZL).
2/22/2017: FDA approved lenalidomide (Revlimid) as maintenance therapy for patients with multiple myeloma following autologous stem cell transplant.
July 2013 UPDATE: Revlimid received FDA approval for use in the treatment of mantle cell lymphoma (MCL) whose disease has relapsed after two prior therapies, one of which included bortezomib.
FDA approved for MDS 2005, for multiple myeloma 2006, orphan drug status CLL
Thalidomide analog immunomodulatory derivative.
February 20, 2015 update: FDA approved revlimid given in combination with dexamethasone as first course treatment for newly diagnosed multiple myeloma.
2/22/2017: FDA approved lenalidomide (Revlimid) as maintenance therapy for patients with multiple myeloma following autologous stem cell transplant.
July 2013 UPDATE: Revlimid received FDA approval for use in the treatment of mantle cell lymphoma (MCL) whose disease has relapsed after two prior therapies, one of which included bortezomib.
FDA approved for MDS 2005, for multiple myeloma 2006, orphan drug status CLL
Thalidomide analog immunomodulatory derivative.
February 20, 2015 update: FDA approved revlimid given in combination with dexamethasone as first course treatment for newly diagnosed multiple myeloma.
Coding
This drug should be coded
Name
Alternate Names
A 56268
A-56268
A56268
Biaxin
Abbreviations
None
Category
Other therapy
Subcategory
Antibiotic
NSC Number
643733
Primary Site
None
Histology
MALT Lymphoma
Remarks
Treatment of the H. pylori infection leads to regression of the lymphoma in about 8 out of every 10 people with gastric MALT lymphoma who showed evidence of an H. pylori infection. The treatment is most successful when the tumor has not extended very far through the stomach wall and has not spread to the lymph nodes.
An initial course of antibiotic treatment for H. pylori eradication is clarithromycin together with either amoxicillin or metronidazole. These antibiotics are usually given with a drug that cuts down the amount of acid the stomach produces (a proton pump inhibitor or 'PPI' drug such as omeprazole). This combination of three drugs is often called ‘triple therapy’ and is taken for 10–14 days.
Coding instructions: Code this drug Other Therapy ONLY when given for MALT lymphoma
An initial course of antibiotic treatment for H. pylori eradication is clarithromycin together with either amoxicillin or metronidazole. These antibiotics are usually given with a drug that cuts down the amount of acid the stomach produces (a proton pump inhibitor or 'PPI' drug such as omeprazole). This combination of three drugs is often called ‘triple therapy’ and is taken for 10–14 days.
Coding instructions: Code this drug Other Therapy ONLY when given for MALT lymphoma
Coding
Please see remarks for additional information